Osimertinib in Resected EGFR-Mutated NSCLC. Reply

N Engl J Med. 2023 Oct 5;389(14):1342. doi: 10.1056/NEJMc2309385.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Acrylamides / therapeutic use
  • Aniline Compounds / therapeutic use
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • ErbB Receptors / genetics
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics

Substances

  • osimertinib
  • Acrylamides
  • Aniline Compounds
  • ErbB Receptors
  • EGFR protein, human